» Articles » PMID: 28358042

Spatial and Molecular Resolution of Diffuse Malignant Mesothelioma Heterogeneity by Integrating Label-free FTIR Imaging, Laser Capture Microdissection and Proteomics

Abstract

Diffuse malignant mesothelioma (DMM) is a heterogeneous malignant neoplasia manifesting with three subtypes: epithelioid, sarcomatoid and biphasic. DMM exhibit a high degree of spatial heterogeneity that complicates a thorough understanding of the underlying different molecular processes in each subtype. We present a novel approach to spatially resolve the heterogeneity of a tumour in a label-free manner by integrating FTIR imaging and laser capture microdissection (LCM). Subsequent proteome analysis of the dissected homogenous samples provides in addition molecular resolution. FTIR imaging resolves tumour subtypes within tissue thin-sections in an automated and label-free manner with accuracy of about 85% for DMM subtypes. Even in highly heterogeneous tissue structures, our label-free approach can identify small regions of interest, which can be dissected as homogeneous samples using LCM. Subsequent proteome analysis provides a location specific molecular characterization. Applied to DMM subtypes, we identify 142 differentially expressed proteins, including five protein biomarkers commonly used in DMM immunohistochemistry panels. Thus, FTIR imaging resolves not only morphological alteration within tissue but it resolves even alterations at the level of single proteins in tumour subtypes. Our fully automated workflow FTIR-guided LCM opens new avenues collecting homogeneous samples for precise and predictive biomarkers from omics studies.

Citing Articles

Metasurface-Enhanced Mid-Infrared Spectrochemical Imaging of Tissues.

Rosas S, Schoeller K, Chang E, Mei H, Kats M, Eliceiri K Adv Mater. 2023; 35(28):e2301208.

PMID: 37186328 PMC: 10524888. DOI: 10.1002/adma.202301208.


PROTEOMAS: a workflow enabling harmonized proteomic meta-analysis and proteomic signature mapping.

Bahl A, Ibrahim C, Plate K, Haase A, Dengjel J, Nymark P J Cheminform. 2023; 15(1):34.

PMID: 36935498 PMC: 10024914. DOI: 10.1186/s13321-023-00710-2.


Cancer proteogenomics: current impact and future prospects.

Mani D, Krug K, Zhang B, Satpathy S, Clauser K, Ding L Nat Rev Cancer. 2022; 22(5):298-313.

PMID: 35236940 DOI: 10.1038/s41568-022-00446-5.


Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine.

Liotta L, Pappalardo P, Carpino A, Haymond A, Howard M, Espina V Expert Rev Proteomics. 2021; 18(10):845-861.

PMID: 34607525 PMC: 10720974. DOI: 10.1080/14789450.2021.1984886.


The application of label-free imaging technologies in transdermal research for deeper mechanism revealing.

Zhang D, Bian Q, Zhou Y, Huang Q, Gao J Asian J Pharm Sci. 2021; 16(3):265-279.

PMID: 34276818 PMC: 8261078. DOI: 10.1016/j.ajps.2020.07.004.


References
1.
Hosako M, Muto T, Nakamura Y, Tsuta K, Tochigi N, Tsuda H . Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker. J Proteomics. 2011; 75(3):833-44. DOI: 10.1016/j.jprot.2011.09.026. View

2.
Kretlow A, Wang Q, Kneipp J, Lasch P, Beekes M, Miller L . FTIR-microspectroscopy of prion-infected nervous tissue. Biochim Biophys Acta. 2006; 1758(7):948-59. DOI: 10.1016/j.bbamem.2006.05.026. View

3.
Niu H, Jiang H, Cheng B, Li X, Dong Q, Shao L . Stromal proteome expression profile and muscle-invasive bladder cancer research. Cancer Cell Int. 2012; 12(1):39. PMC: 3489783. DOI: 10.1186/1475-2867-12-39. View

4.
Pilling M, Gardner P . Fundamental developments in infrared spectroscopic imaging for biomedical applications. Chem Soc Rev. 2016; 45(7):1935-57. DOI: 10.1039/c5cs00846h. View

5.
Rifai N, Gillette M, Carr S . Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24(8):971-83. DOI: 10.1038/nbt1235. View